R

RE M. C.

Last name: RE M. C.

2010 (v1)

Publication

Metadata-only

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine

Maserati R. De Silvestri A. Uglietti A.

OBJECTIVE: To compare the emergence of drug-resistant HIV variants at failure of lamivudine (3TC)/tenofovir (TDF)-containing or emtricitabine (FTC)/TDF-containing HAART as a consequence of the different 3TC and FTC intracellular half-lives. DESIGN: Retrospective evaluation of 859 patients selected from an Italian HIV resistance database...

Uploaded on: April 14, 2023
2017 (v1)

Publication

Metadata-only

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

Rossetti B. Gagliardini R. Meini G.

Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation...

Uploaded on: April 14, 2023